Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged Amarin Pharma
Amarin: What does Amarin’s reply appellate brief say?

Amarin’s appeal of the district court’s decision invalidating the Marine patents is now fully briefed. Amarin’s reply brief is strong, but does it tip the odds in favor of Amarin prevailing on the appeal?

Read More
Markman AdvisorsAmarin Pharma, Amarin, $AMRN, AMRN, vacepa, Hikma, Dr. Reddy's, Federal Circuit, patent, hypertriglyceridemia, triglycerides, LDL-C, Dr. Bhatt, Bhatt, EPA, Epadel, Lovasa, Heinecke, Zachary Silbersher, Silbersher Comments
Amarin: What does Amarin’s opening appellate brief say?

On May 12, 2020, Amarin ($AMRN) filed its opening appeal brief in its appeal of the decision by the District of Nevada wherein the Honorable Miranda M. Du invalidated six patents that were asserted against prospective generics, Hikma and Dr. Reddy’s. What does the brief say?

Read More
Markman AdvisorsAmarin, Amarin Pharma, $AMRN, Hikma, Dr. Reddy's, Hatch-Waxman, patent, Federal Circuit, Vascepa, EPA, DHA, triglycerides, cyclobenzaprine, secondary considerations, Mori, LDL-C, hypertriglyceridemia, Zachary Silbersher, Silbersher Comments